Association of Plasma Connective Tissue Growth Factor Levels with Hyperthyroid Heart Disease

Abstract

Hyperthyroid heart disease (HHD) is one of the most severe complications of overt hyperthyroidism and increases the risk of mortality in affected patients. Early identification of patients at a higher risk of developing HHD can improve clinical outcomes through active surveillance and management. Connective tissue growth factor (CTGF), a secreted extracellular protein, plays a significant role in cardiac remodeling and dysfunction. We aimed to investigate the association between plasma CTGF level and the risk of HHD in this study. A total of 142 overt hyperthyroid patients without HHD and 99 patients with HHD were included. The plasma CTGF levels were measured using ELISA kits. Routine clinical medical data and echocardiography parameters were recorded for analysis. The plasma CTGF level was significantly higher in patients with HHD than in those without HHD (P=0.002). The plasma CTGF level was positively correlated with free triiodothyronin, tryrotropin receptor antibody, troponin I and lactate dehydrogenase levels and the left atrium diameters, right atrium diameters, and right ventricular end-diastolic diameters (all P<0.05). Logistic regression analysis showed that quartiles 3 and 4 of plasma CTGF levels were significantly associated with the increased risk of HHD (crude OR: 2.529; 95% CI: 1.188–5.387). However, after adjustment for the potentially confounding variables, quartile 4 alone was significantly associated with the higher risk of HHD relative to quartile 1. Hyperthyroid patients with HHD display higher plasma CTGF levels. Furthermore, CTGF is an independent risk factor for HHD. Therefore, the plasma CTGF level may be a potential biomarker for the risk of HHD.

Keywords

connective tissue growth factor / hyperthyroid / heart / thyroid hormone

References

[1] TaylorPN, AlbrechtD, ScholzA, et al.. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol, 2018, 14(5): 301-316

[2] BrandtF, ThvilumM, AlmindD, et al.. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One, 2013, 8(6): e66711

[3] BrandtF, GreenA, HegedusL, et al.. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol, 2011, 165(4): 491-497

[4] OsunaPM, UdovcicM, SharmaMD. Hyperthyroidism and the Heart. Methodist Debakey Cardiovasc J, 2017, 13(2): 60-63

[5] JabbarA, PingitoreA, PearceSH, et al.. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol, 2017, 14(1): 39-55

[6] SiuCW, YeungCY, LauCP, et al.. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart, 2007, 93(4): 483-487

[7] DillmannW. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev, 2010, 15(2): 125-132

[8] ChenMM, LamA, AbrahamJA, et al.. CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol, 2000, 32(10): 1805-1819

[9] AhmedMS, OieE, VingeLE, et al.. Connective tissue growth factor—a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol, 2004, 36(3): 393-404

[10] MessaoudiS, GravezB, TarjusA, et al.. Aldosteronespecific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension (Dallas, Tex: 1979), 2013, 61(2): 361-367

[11] RecchiaAG, FiliceE, PellegrinoD, et al.. Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. J Mol Cell Cardiol, 2009, 46(3): 352-359

[12] WangX, McLennanSV, AllenTJ, et al.. Adverse effects of high glucose and free fatty acid on cardiomyocytes are mediated by connective tissue growth factor. Am J Physiol Cell Physiol, 2009, 297(6): C1490-1500

[13] ChiH, FengH, ShangX, et al.. Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure. Cardiology, 2019, 143(3–4): 77-84

[14] KoitabashiN, AraiM, NiwanoK, et al.. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail, 2008, 10(4): 373-379

[15] TanCY, WongJX, ChanPS, et al.. Yin Yang 1 Suppresses Dilated Cardiomyopathy and Cardiac Fibrosis Through Regulation of Bmp7 and Ctgf. Circ Res, 2019, 125(9): 834-846

[16] KoshmanYE, SternlichtMD, KimT, et al.. Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy. J Mol Cell Cardiol, 2015, 89(PtB): 214-222

[17] HayataN, FujioY, YamamotoY, et al.. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun, 2008, 370(2): 274-278

[18] PanekAN, PoschMG, AleninaN, et al.. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One, 2009, 4(8): e6743

[19] HuntKJ, JaffaMA, GarrettSM, et al.. Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. Diabetes Care, 2018, 41(4): 840-846

[20] RossDS, BurchHB, CooperDS, et al.. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 2016, 26(10): 1343-1421

[21] ZhangX, ChenL, ShengJ, et al.. The Association of Autoantibodies in Hyperthyroid Heart Disease Combined with Pulmonary Hypertension. Int J Endocrinol, 2019, 2019: 9325289

[22] WangQ, LiC, DiS, et al.. Clinical efficacy and safety of traditional Chinese patent medicine for hyperthyroid heart disease: study protocol for a systematic review and meta-analysis. Medicine (Baltimore), 2018, 97(45): e13076

[23] LangRM, BadanoLP, Mor-AviV, et al.. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2015, 28(1): 1-39 e14

[24] JunJI, LauLF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov, 2011, 10(12): 945-963

[25] Vargas-UricoecheaH, Bonelo-PerdomoA, Sierra-TorresCH. Effects of thyroid hormones on the heart. Clin Investig Arterioscler, 2014, 26(6): 296-309

[26] Carneiro-RamosMS, DinizGP, NaduAP, et al.. Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol, 2010, 105(3): 325-335

[27] LipsonKE, WongC, TengY, et al.. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair, 2012, 5(Suppl 1): S24

[28] ChiH, FengH, ShangX, et al.. Circulating Connective Tissue Growth Factor Is Associated with Diastolic Dysfunction in Patients with Diastolic Heart Failure. Cardiology, 2019, 143(3–4): 77-84

[29] HuangYM, ChangPC, WuSB, et al.. Expression and clinical significance of connective tissue growth factor (CTGF) in Graves’ ophthalmopathy. Br J Ophthalmol, 2017, 101(5): 676-680

[30] ChenJQ, GuoYS, ChenQ, et al.. TGFbeta1 and HGF regulate CTGF expression in human atrial fibroblasts and are involved in atrial remodelling in patients with rheumatic heart disease. J Cell Mol Med, 2019, 23(4): 3032-3039